Shares of Mesoblast Limited (NASDAQ:MESO) have been assigned an average recommendation of “Hold” from the eight ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $14.25.
Several equities research analysts have recently commented on the stock. Maxim Group set a $14.00 price target on shares of Mesoblast Limited and gave the stock a “buy” rating in a research report on Wednesday, August 16th. CIBC assumed coverage on shares of Mesoblast Limited in a report on Thursday, August 31st. They set an “outperform” rating and a $16.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating on shares of Mesoblast Limited in a report on Wednesday, August 23rd. Oppenheimer Holdings, Inc. assumed coverage on shares of Mesoblast Limited in a report on Thursday, August 31st. They set an “outperform” rating and a $16.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Mesoblast Limited from a “sell” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Tuesday, May 23rd.
A hedge fund recently raised its stake in Mesoblast Limited stock. Princeton Capital Management Inc. raised its stake in Mesoblast Limited (NASDAQ:MESO) by 15.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the quarter. Princeton Capital Management Inc. owned about 0.20% of Mesoblast Limited worth $1,398,000 at the end of the most recent reporting period. 2.95% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Mesoblast Limited (NASDAQ MESO) traded down 3.8758% during midday trading on Thursday, hitting $5.8828. 23,453 shares of the company traded hands. The stock’s 50-day moving average is $6.79 and its 200 day moving average is $8.25. The stock’s market capitalization is $499.36 million. Mesoblast Limited has a 12-month low of $4.01 and a 12-month high of $12.50.
ILLEGAL ACTIVITY NOTICE: “Mesoblast Limited (MESO) Receives $14.25 Consensus Price Target from Analysts” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/09/10/mesoblast-limited-meso-receives-14-25-consensus-price-target-from-analysts.html.
About Mesoblast Limited
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.